Reversal of late septic shock with supraphysiologic doses of hydrocortisone
- PMID: 9559600
- DOI: 10.1097/00003246-199804000-00010
Reversal of late septic shock with supraphysiologic doses of hydrocortisone
Abstract
Objectives: Preliminary studies have suggested that low doses of corticosteroids might rapidly improve hemodynamics in late septic shock treated with catecholamines. We examined the effect of hydrocortisone on shock reversal, hemodynamics, and survival in this particular setting.
Design: Prospective, randomized, double-blind, placebo-controlled study.
Setting: Two intensive care units of a University hospital.
Patients: Forty-one patients with septic shock requiring catecholamine for >48 hrs.
Interventions: Patients were randomly assigned either hydrocortisone (100 mg i.v. three times daily for 5 days) or matching placebo.
Measurements and main results: Reversal of shock was defined by a stable systolic arterial pressure (>90 mm Hg) for > or =24 hrs without catecholamine or fluid infusion. Of the 22 hydrocortisone-treated patients and 19 placebo-treated patients, 15 (68%) and 4 (21%) achieved 7-day shock reversal, respectively, a difference of 47% (95% confidence interval 17% to 77%; p = .007). Serial invasive hemodynamic measurements for 5 days did not show significant differences between both groups. At 28-day follow-up, reversal of shock was higher in the hydrocortisone group (p = .005). Crude 28-day mortality was 7 (32%) of 22 treated patients and 12 (63%) of 19 placebo patients, a difference of 31% (95% confidence interval 1% to 61%; p = .091). Shock reversal within 7 days after the onset of corticosteroid therapy was a very strong predictor of survival. There were no significant differences in outcome in responders and nonresponders to a short corticotropin test. The respective rates of gastrointestinal bleeding and secondary infections did not differ between both groups.
Conclusions: Administration of modest doses of hydrocortisone in the setting of pressor-dependent septic shock for a mean of >96 hrs resulted in a significant improvement in hemodynamics and a beneficial effect on survival. These beneficial effects do not appear related to adrenocortical insufficiency.
Comment in
-
Corticosteroids in septic shock: resurrection of the last rites?Crit Care Med. 1998 Apr;26(4):627-30. doi: 10.1097/00003246-199804000-00002. Crit Care Med. 1998. PMID: 9559592 No abstract available.
-
Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal.Crit Care Med. 1998 Apr;26(4):630-3. doi: 10.1097/00003246-199804000-00003. Crit Care Med. 1998. PMID: 9559593 No abstract available.
-
Steroid therapy for late septic shock.Crit Care Med. 1999 Jul;27(7):1402. doi: 10.1097/00003246-199907000-00050. Crit Care Med. 1999. PMID: 10446849 No abstract available.
-
Steroids in sepsis: which p value is correct?Crit Care Med. 1999 Nov;27(11):2602. doi: 10.1097/00003246-199911000-00064. Crit Care Med. 1999. PMID: 10579305 No abstract available.
Similar articles
-
Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.Crit Care Med. 1999 Apr;27(4):723-32. doi: 10.1097/00003246-199904000-00025. Crit Care Med. 1999. PMID: 10321661 Clinical Trial.
-
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.JAMA. 2002 Aug 21;288(7):862-71. doi: 10.1001/jama.288.7.862. JAMA. 2002. PMID: 12186604 Clinical Trial.
-
Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock.Crit Care Med. 2005 Nov;33(11):2457-64. doi: 10.1097/01.ccm.0000186370.78639.23. Crit Care Med. 2005. PMID: 16276166 Clinical Trial.
-
[Cortisol in critically ill patients with sepsis: physiologic functions and therapeutic implications].Wien Klin Wochenschr. 2000 Apr 21;112(8):341-52. Wien Klin Wochenschr. 2000. PMID: 10849939 Review. German.
-
Hydrocortisone in Vasodilatory Shock.Crit Care Clin. 2019 Apr;35(2):263-275. doi: 10.1016/j.ccc.2018.11.005. Epub 2019 Jan 28. Crit Care Clin. 2019. PMID: 30784608 Review.
Cited by
-
Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.Vasc Health Risk Manag. 2006;2(1):3-18. doi: 10.2147/vhrm.2006.2.1.3. Vasc Health Risk Manag. 2006. PMID: 17319465 Free PMC article. Review.
-
Advances in Sepsis Treatment.Curr Infect Dis Rep. 2004 Oct;6(5):354-360. doi: 10.1007/s11908-004-0033-2. Curr Infect Dis Rep. 2004. PMID: 15461885
-
Immune Effects of Corticosteroids in Sepsis.Front Immunol. 2018 Jul 30;9:1736. doi: 10.3389/fimmu.2018.01736. eCollection 2018. Front Immunol. 2018. PMID: 30105022 Free PMC article. Review.
-
The diagnosis of adrenal insufficiency in the critically ill patient: does it really matter?Crit Care. 2006;10(6):176. doi: 10.1186/cc5105. Crit Care. 2006. PMID: 17147770 Free PMC article.
-
A Single-Center Review of Prescribing Trends and Outcomes of Corticosteroid Replacement Therapy in Critically Ill Children with Septic Shock.Open Crit Care Med J. 2010 Jan 1;3:51-56. doi: 10.2174/1874828701003010051. Open Crit Care Med J. 2010. PMID: 21666764 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical